Innate Pharma SA (IPHYF) Stock Statistics & Valuation Metrics

Innate Pharma SA has a market cap or net worth of $205.59M. The enterprise value is ―.

Innate Pharma SA has 92,176,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma SA’s return on equity (ROE) is -5.60 and return on invested capital (ROIC) is -59.12%.

The current PE Ratio of Innate Pharma SA is -3.16. Innate Pharma SA’s PEG ratio is 0.08.

In the last 12 months, Innate Pharma SA had revenue of 12.62M and earned -49.47M in profits. Earnings per share was -0.61.

In the last 12 months, operating cash flow was -6.90M and capital expenditures -391.00K, giving a free cash flow of -7.29M billion.

Innate Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma SA upcoming earnings date is Sep 17, 2025, TBA Not Confirmed.

Innate Pharma SA as a current ratio of 2.60, with Debt / Equity ratio of 350.86%

In the past 12 months, Innate Pharma SA has paid -7.49M in taxes.

Innate Pharma SA EV to EBITDA ratio is -2.37, with an EV/FCF ratio of -16.61.

Innate Pharma SA has $80.77M in cash and marketable securities with €31.00M in debt, giving a net cash position of -$49.77M billion.

Gross margin is -100.34%, with operating margin of -468.02%, and net profit margin of -391.94%.

The average price target for Innate Pharma SA is $3.52, which is 11.43% higher than the current price. The consensus rating is Hold